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Neuroinﬂammation has been implicated in the pathology of Alzheimer’s disease (AD) for decades. Still it has not been fully
understood when and how inﬂammation arises in the course of AD. Whether inﬂammation is an underling cause or a resulting
condition in AD remains unresolved. Mounting evidence indicates that microglial activation contributes to neuronal damage in
neurodegenerative diseases. However, also beneﬁcial aspects of microglial activation have been identiﬁed. The purpose of this
review is to highlight new insights into the detrimental and beneﬁcial role of neuroinﬂammation in AD. It is our intention to
focus on newer controversies in the ﬁeld of microglia activation. Precisely, we want to shed light on whether neuroinﬂammation
is associated to brain tissue damage and functional impairment or is there also a damage limiting activity. In regard to this, we
discuss the limitations and the advantages of anti-inﬂammatory treatment options and identify what future implications might
result from this underling neuroinﬂammation for AD therapy.
1.Introduction
The pathology of Alzheimer’s disease (AD) is characterized
by the deposition of amyloid-β (Aβ) plaques in the brain
parenchyma and neuroﬁbrillary tangles within neurons [1].
Apart from the disease’s distinct pathological mark-
ers, its neurodegenerative conditions are characterized by
chronic neuroinﬂammatory processes. Yet, those inﬂamma-
tory markers are not exclusively associated with AD. Also
brains of “healthy aged” individuals show concentrations
of serum markers related to inﬂammation, homocysteine
and cholesterol homeostasis are associated with cognitive
functioning in the nondemented healthy aging population
[2]. In the AD pathology, these aging-related inﬂammatory
processes are increased. The suggestion that inﬂammation
may participate in AD ﬁrst came up more than two decades
ago. As several clinical trials have shown a beneﬁcial eﬀect
for nonsteroidal anti-inﬂammatory drugs for the occurrence
andcourseofAD,theinﬂammatoryhypothesisinADgained
a lot of attention. In regard to treatment and prevention
of AD, several classes of medications have emerged to the
market, which improve the cognitive symptoms of this
disorder (e.g. the cholinesterase inhibitors). But the relief
that these drugs provide remains symptomatic—so it is
a major goal for the future to develop eﬀective disease-
modifying therapy. Diﬀerent substantial eﬀorts have been
made to identify potential strategies to ameliorate or prevent
AD pathology, with data stemming from basic research as
well as from animal and epidemiological studies. Because
many investigators have concluded that neuroinﬂammation
contributes to neuronal damage in the brain during AD
[3, 4], the use of anti-inﬂammatory drugs as a possible
treatment option has been widely investigated [5–7]. Anti-
inﬂammatory therapy has therefore been credited as a
strategy for reducing the risk or slowing the progression of
AD. However, the results of these studies remain inconsistent
[8].
Until now, many questions regarding the inﬂammatory
response are still unresolved. Discussion continues whether
neuroinﬂammation is an underling cause or a resulting
condition in AD.
There are several studies showing that an intact immune
response including intact T cell immunity is a prerequisite
for cognitive function. T cell deﬁcient mice show impaired2 International Journal of Alzheimer’s Disease
learning abilities, which can be reversed with T cell substitu-
tion [9, 10].
Inﬂammation in the brain is characterized by activation
ofglialcells(mainlymicrogliaandastrocytes)andexpression
of key inﬂammatory mediators as well as neurotoxic free
radicals. It has been suggested that neuroinﬂammation is
associated with neurodegenerative disorders—both acute
(e.g. stroke, injury) and chronic (e.g. multiple sclerosis,
AD). In this context, microglia cells play a crucial role
and therefore microglia and cytokines have been extensively
studied in these conditions. In the central nervous system,
microglia are the resident phagocytes of the innate immune
system. Microglia are found in a highly activated state in
close anatomical proximity to senile plaques within the AD
brain. In this activated state, microglia produce various
proinﬂammatory cytokines and other immune mediators
that create a neurotoxic milieu leading to disease progression
[4, 11].
The purpose of this review is to highlight our new
insights into the role of neuroinﬂammation in the patho-
physiology of AD. It is our intention to focus on newer con-
troversies in the ﬁeld of microglia activation and its function
in AD pathology. For this, we asked ourselves some ques-
tions: are neuroinﬂammatory alterations neuroprotective—
or are they rather an underlying cause of AD? And what
strategies result from this underling neuroinﬂammation for
future treatment options?
2. Characteristicsof NeuroinﬂammationinAD
The relevance of neuroinammation to AD pathology has
been established by multiple lines of direct and indirect evi-
dence. One argument is that increased microglial activation
has been shown in regions associated with Aβ deposition
[12]. Upregulated inammatory mechanisms colocalize in the
AD brain with those regions that exhibit high levels of AD
pathology (e.g. frontal and limbic cortex) and are minimal
in brain regions with low AD pathologic susceptibility (e.g.
cerebellum) [13].
As a second point, many of the inammatory mechanisms
that have been uncovered in the AD brain are established
to be cytotoxic in the periphery. Therefore it seems likely
that they are also cytotoxic in the brain, an organ that is
sensitive to inammation (e.g. meningitis, edema). However,
inﬂammation in the brain is diﬀerent from inﬂammation
in the periphery. AD brains lack the classical hallmarks of
inﬂammation such as neutrophil inﬁltration and perivascu-
lar mononuclear cuﬃng. As for other neurodegenerative dis-
eases, a local inﬂammatory reaction is sustained by activated
microglia and reactive astrocytes. This is indicated by the
presence of antigens associated with microglia activation and
inﬂammatory mediators, such as factors of the complement
system, cytokines, and free radicals [14].
For AD a huge variety of proinﬂammatory markers
have been identiﬁed, whereas this was not the case for
other forms of dementia. A relevant reduction of monocyte
chemotactic protein-1 levels in the grey matter in dementia
patients has been shown. For interleukin-6 (IL) and related
markers of this proinﬂammatory cytokine system, decreases
were observed in the demented population [15, 16]. It is
discussed,however,whetherthisdecreaseisrelatedtofurther
psychopathological symptoms such as depression [16]. On
the other hand, IL-6 has also neuroprotective properties
and decreased IL-6 might be associated with decreased
neuroprotection [17],
Only modest elevations of inammatory markers are
found in the autopsy of patients lacking a clinical pre-
sentation of dementia but who exhibit suﬃcient Aβ and
neurobrillary tangles to otherwise qualify for the diagnosis
of AD. Their level of inﬂammatory markers is signicantly
greaterthanlevelsofnondementedpatients,butdramatically
less than AD patients [18]. These ﬁndings further strengthen
that an inﬂammation is a necessity for clinical symptoms of
AD.
There also is direct evidence of inammatory toxicity
in the AD brain. For instance, complement xation and
lysis of neurites could be demonstrated ultrastructurally in
Alzheimer’s disease cortex, but in contrast it was only very
weakly detected in nondemented elderly cortex under the
same conditions [19].
Finally, many clinical and animal studies have strongly
suggested that especially nonsteroidal anti-inﬂammatory
drugs (NSAIDs) could be used as preventive or treatment
strategies in AD. This aspect is further discussed in a later
section of this paper, where we focus on anti-inﬂammatory
treatment.
Even though there are many indicators that neuroin-
ﬂammation plays a key role in AD pathology, this does not
answer which of these inﬂammatory activities are causing
disease progression. The question remains: do some of these
processes help to ﬁght against the disease? In order to
address this, the role of microglia seems important, because
these cells are known for neuroprotective and degenerative
functions.
3. Controversy: Do Activated Microglia
Cause Neuroprotection or -Degeneration
int h eA DB rain ?
Microglia are one of three glial cell types in the central
nervous system (CNS). They play an important role as
residentimmunocompetentandphagocyticcellsintheevent
of injury and disease. Del Rio Hortega determined in 1927
that microglia belong to a distinct glial cell type apart
from astrocytes and oligodendrocytes [20]. Since the 1970s
there has been wide recognition that microglia are immune
eﬀectors in the CNS that respond to pathological conditions
and participate in initiation and progression of neurological
disorders (including AD) by releasing potentially cytotoxic
molecules such as proinﬂammatory cytokines, reactive oxy-
gen intermediates, proteinases, and complement proteins
[21]. This means that their phagocytic function can be
beneﬁcial while their inﬂammation related functions might
be detrimental.
Several studies give evidence for an increased number of
morphologically reactive microglia in AD brains compared
to nondemented individuals [22, 23]. The location of theseInternational Journal of Alzheimer’s Disease 3
reactive microglia has been indentiﬁed directly around
plaques [24]. This ﬁnding has been veriﬁed in a recent
imaging study, which showed increased microglial activation
in regions associated with amyloid deposition [12]. Up to
now, the exact timing of this association could not be
identiﬁed. Microgliosis might be an early component of
the disease process and not necessarily dependent upon Aβ
plaque interaction as a stimulus. What is known so far
is that activation of microglia by Aβ ﬁbrils is associated
with a chemotactic response and extensive clustering of
microglia around Aβ plaques in the AD brain [25]. These
ﬁndingsindicatetheprominentroleofmicroglialcellsinAD.
Nonetheless it remains unclear, whether their functions are
beneﬁcial or detrimental.
The following section explains the checkered role of
activated microglia in AD pathology.
4.NeuroprotectivePropertiesof
MicrogliainAD
Is there a possibility that activated microglia cells are
beneﬁcial in neurodegenerative diseases? It is known that the
microglia population can be neuroprotective by degrading
Aβ plaques in AD. Mouse models found that microglia
mainly recruit macrophages from the periphery that then
transform into microglia in the brain. Therefore most of the
microglia that were associated with plaques in the mouse
brain came from the bone marrow [26]. Furthermore it
has been suggested that newly recruited microglia have
diﬀerent phagocytotic properties than intrinsic microglia,
which is important for Aβ elimination. Lysosmes from the
macrophage cell line are more acidic than those of microglial
lysosomes [27]. This indicates that microglia derived from
the periphery might be more eﬃcient in eliminating Aβ
than brain microglia. Furthermore, phagocytic activity of
microglia is dampened by proinﬂammatory cytokines like
tumor necrosis factor α (TNF) [28]. These ﬁndings show
that microglia that are committed to an inﬂammatory
response may have a lower phagocytotic capacity, than newly
recruited microglia. In mouse models of AD it could be
demonstratedthatanti-inﬂammatorydrugslikeminocycline
improve cognitive functions and reduce the activation of
microglial cells but do not alter the Aβ plaques deposition
and distribution [29]. Seabrook et al. showed in amyloid
precursor protein transgenic mice an age dependent eﬀect
of minocycline: in young animals the drug increased the
amyloid load indicating a beneﬁcial eﬀect of microglia in
clearing amyloid [30]. Not only for AD minocycline was
investigated as a potential treatment, also in schizophre-
nia an add-on therapy with minocycline appeared to be
eﬀective on the cognitive performance by reducing a broad
range of psychotic symptoms [31]. On the other hand an
additional mechanism might help microglia cells with the
elimination process. Transforming growth factor-β 1h a s
been demonstrated to promote microglial Aβ clearance and
reduce plaque burden [32]. This could support the idea that
microglial activation is useful in the clearance of Aβ.
A further suggestion for the beneﬁcial role of microglia is
that neuroprotection results from the microglial glutamate
removal. Glutamate has been indentiﬁed as a relevant
neurotoxic substance that acts through N-methyl-D-aspartic
acid(NMDA)receptorsonneuronsandcanleadtoincreased
neuronal cell death. Microglial cells can increase their capac-
ity to take up glutamate upon stimulation with lipopolysac-
caride (LPS) over a mechanism that is TNFα dependent
[33]. For AD this microglial function could be relevant
because memantine (the NMDA receptor antagonist) has
been shown to improve cognition, function (activities of
daily living), agitation, and delusions in AD patients [34].
Taken this together, microglial cells are important for the
control of glutamate levels and might therefore contribute
to neuronal survival. There is also evidence that microglia
are capable of secreting neurotrophic or neuron survival
factors (e.g. nerve growth factor and neurotrophin 3) upon
activation via inﬂammation or injury [35].
A recent review explains that microglia—when they are
challenged—may adapt to diﬀerent stimulatory contexts and
pass through a sequence of reactive proﬁles. This is in line
with the ﬁnding that microglia are not just “resting” but have
active sensor and versatile functions [36].
Are most microglial cells functions beneﬁcial in AD?
Several studies suggest an overbalance of the detrimental
microglial properties. This issue is discussed in the next
section.
5. Microglia—AreThey Responsible for
Neurodestructionand-Degeneration?
In order to address this question, it is important to focus
on timing. One must investigate when microglial activity
begins during the time course of the disease. An increase in
microglial activation has been observed in very early stages
of AD. This increase surprisingly disappeared over time [37].
The suggestion of Vehmas et al. strengthens the assumption
that microglial activation begins early in disease progression
[37]. This could be a hint that microglia initially try to
eliminate Aβ, but over time of the disease fail and therefore
decrease their activity. Alternatively, the microglial role in
AD could be detrimental and they initiate the underlying
AD pathology. In order to further evaluate this issue, a
closer look needs to be taken on what causes the microglial
activation in AD and it seems important to distinguish
between acute and chronic stimulation of microglial cells.
While an acute insult may trigger oxidative and nitrosative
stress, it is typically short-lived and unlikely to be harmful
to long-term neuronal survival. Therefore it is believed that
an acute neuroinﬂammatory response is generally beneﬁcial
to the CNS, since it tends to minimize further injury and
contributes to repair of damaged tissue. The opposite is the
case for a chronic stimulation: chronic neuroinﬂammation
is most often detrimental and damaging to nervous tissue.
Thus, whether neuroinﬂammation has beneﬁcial or harmful
outcomes in the brain may depend critically on the duration
of the inﬂammatory response. The progressive deposition
of Aβ in AD disease might provide a chronic stimulus
to microglial cells. Also the chemotactic functions of Aβ
to attract microglia contribute further to the ongoing4 International Journal of Alzheimer’s Disease
inﬂammatoryprocess[25].Theratiooftheproinﬂammatory
cytokine IL-1β to the anti-inﬂammatory cytokine IL-10 is
drastically elevated in the serum of AD patients, giving these
patients a deﬁnite long-term proinﬂammatory proﬁle [38],
indicating a chronic neuroinﬂammatory state of the CNS. In
addition, the accumulating loss of neurons that characterizes
AD further contributes to generation of debris and keeps
microglia activated indeﬁnitely maintaining microglia in an
activated state long term. This data indicates that in AD
the inﬂammation might be rather chronic and therefore
contributing to disease progression.
There is also the emerging idea that an inﬂamed CNS
environment may inﬂuence the ability of microglia to
contribute to plaque deposition rather than plaque removal
[28]. This strongly suggests that the microenvironment of
the brain can inﬂuence whether microglia perform beneﬁcial
or deleterious functions in pathophysiological states. This
means that microglia cells functionally adapt to their envi-
ronment[36].Recentstudiesshowthatinresponsetocertain
environmental toxins and endogenous proteins, microglia
can enter an overactivated state and release reactive oxygen
species (ROS) that cause neurotoxicity [39]. Overactivated
microglia can be detected using imaging techniques and
therefore this knowledge oﬀers an opportunity not only for
early diagnosis, but eventually also for the development of
targeted anti-inﬂammatory therapies that might diminish
the progression of the disease [21].
In addition, activated microglia release the excitotoxin
quinolinic acid [40], and microglia activated by AD plaques
produce an apparently novel amine that evokes fulminant
excitotoxicity [41]. One interesting implication of an excito-
toxic contribution to inammatory mechanisms is the poten-
tial for limited damage to functional cellular compartments.
Because excitatory amino acid receptors are restricted to
synapses and dendrites, these subcellular compartments are
preferentially vulnerable.
As a result, microglia-produced excitotoxins may lead
to cognitive impairment that is not necessarily correlated
with neuronal cell loss [3]. However, activated microglia
do not only produce neurotoxic metabolites. Some of
their products like 3-hydroxyanthralinic acid (which is—
like quinolinic acid—one of the downstream products of
the tryptophan metabolism) exert antioxidant and anti-
inﬂammatory functions [42, 43]. Therefore the balance
of these products that result from activated microglia is
important for the inﬂammation process.
To sum up the results from microglial studies: clear
indications for the important role of neuroinﬂammation
contributing to disease progression in AD were found.
However, some parts of microglial activation might also be
beneﬁcial during the course of AD. These issues are shown in
Figure 1.
6.TheRole of COXInhibitors
in Neurodegeneration
As explained above, neuroinﬂammation is a critical event
in AD. It has been suggested that anti-inammatory therapy
could be benecial in delaying the onset or slowing the
progression of AD.
Cyclooxygenase (COX) is a unique enzyme. First, it
exhibits two catalytic activities, a bis-oxygenase activity,
which catalyses prostaglandin G2 (PG) formation from
arachidonic acid and a peroxidase activity, which reduces
PG G2 to PG H2. The peroxidase activity also results in
the production of free radicals, which are in part utilized
by COX itself [44]. Although NSAIDs may have other
eﬀects as well, it is generally assumed that their primary
mechanism of action is by competitive inhibition of COX
activity, thereby reducing the production of inammatory
prostaglandins from membrane-derived arachidonate. COX
not only helps mediate production of prostaglandins and
other inammatory factors, it is itself upregulated by pro-
inammatory mediators [44].
In AD, Aβ neurotoxicity may result from several mech-
anisms, most likely in combination. These mechanisms
include oxidative damage, direct cytotoxicity, and induction
of destructive inﬂammatory mechanisms; eﬀorts have been
directed at the control of each of these processes [45]. See
Figure 1 for the involvment of COX in the AD pathology.
The treatment of AD with NSAIDs is one of the most
promising approaches.
7.Possible Mechanismsof
Action of NSAID in AD
If NSAIDs are beneﬁcial in AD, the presumed mechanism
would be inhibition of COX expressed in the brain. Both
COX-1 and COX-2 are expressed there and COX-2 plays
a unique role in the brain compared to the periph-
ery: only in the brain COX-2 is expressed constitutively
whereas elsewhere the expression is activation-dependent.
Although in vivo the majority of COX-2 appears to be
made in neurons, COX-2 was also seen in rat astrocytes
and microglia [46]. It has been demonstrated that COX-
inhibiting NSAIDs reduce microglial activation following
infusionofAβinrats[47].Neuronalstress,suchasischaemia
and excitotoxicity, is associated with strong upregulation
of neuronal COX-2 expression. This suggests that COX-2
is involved in neurotoxic mechanisms and may therefore
represent a target for drug therapy in the treatment of AD
[48, 49].
Several studies provide the background for possible
mechanisms of action of NSAIDs in AD. Neuronal COX-2
is upregulated in response to exposure to Aβ [50], and focal
increasesinCOX-2havebeenshownintheregionofamyloid
plaquesindoubletransgenicmicecarryinggenesthatencode
bothmutantAPPandmutantpresenilin1[51].Manystudies
seemtoshowthatCOX-2inhibitionconfersneuroprotection
[52–55]. Some studies have revealed an upregulation of
neuronal COX-2 in the brains of patients with AD [56, 57],
though this has not been a universal ﬁnding [58, 59]. One
explanation for the variation of COX expression is the short
half-life of COX-2 transcripts or individual variability of
inﬂammatory-related processes.International Journal of Alzheimer’s Disease 5
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Figure 1: possible interactions of COX-inhibitors and Alzheimer‘s disease pathology. The fair arrows show neurotoxic properties of Aβ,
COX-expression cytokines. In addition it is indicated that COX-inhibitors block COX-expression, activated microglia, ROS, and Aβ. ROS:
radical oxygen species; COX: cyclooxygenase; Aβ:a m y l o i dβ.
Another principle of how NSAIDs could act, comes
from the ﬁnding that prostaglandin E2 levels are elevated
in patients with AD, especially in early stages of the disease
[60]. Therefore NSAIDs blocking prostaglandin E2 synthesis
might be beneﬁcial. This issue is further strengthened
by glial culture studies indicating that prostaglandins,
particularly prostaglandin E, alter the production of several
inammation-related molecules, including IL-6, chemokines,
and APP [61–63].
In addition to the more traditional inammatory mech-
anisms associated with COX, unique functions of COX-
mediated damage may also occur in the AD brain. For
example, several of the prostanoid products of arachidonate
metabolism potentiate glutamate excitotoxicity, and COX-
2 overexpressing transgenic mice exhibit increased neuronal
susceptibility to excitotoxic insult [64].
Some of the previously mentioned studies of COX
in ischemia also suggest that intraneuronal COX-2 levels
may contribute to neuronal death by production of free
radicals [65]. In addition, increased COX-2 levels in AD
neurons may directly damage neurons or increase their
vulnerability to other detrimental processes occurring in AD
brain [65]. Thus, NSAIDs actions to inhibit COX-mediated
production of apoptotic factors by neurons could be one of
the mechanisms by which these drugs seem to exert benecial
eﬀects in AD.
Another non-COX-dependent mechanism of NSAIDs is
to attenuate inammatory processes in a manner by directly
activating the peroxisome proliferator-activated receptor
gamma (PPARγ), a receptor and nuclear transcription
factor [66–68]. PPARγ is a member of the orphan nuclear
receptor family and in cells of monocytic lineage, including
microglia, acts to suppress the expression of a broad range
of proinammatory genes [66, 68]. Some NSAIDs act as
PPARγ agonists, directly binding to it and initiating its
transcriptional activity. Activation of PPARγ inhibits the Aβ-
stimulated activation of microglia and monocytes and their
secretion of proinammatory and neurotoxic products. For
example, PPARγ agonists act to inhibit the Aβ-stimulated
expression of IL-6 and TNF-alpha [69], by microglia and
monocytes, and to prevent Aβ-mediated conversion of
microglia into an activated phenotype [70].
A further underlying mechanism of AD pathology is
oxidative stress [71, 72]. Activated microglial cells are known
to release ROS, which might possibly cause this oxidative
stress. Though glia cells can also exhibit antioxidative
functions by releasing hemeoxygenase-1 (HO-1) triggered
by accumulation of 3-hydroxyanthralinic acid (3-HAA), a
down-stream product of the tryptophan metabolism. The
association of neuronal injury in AD and oxidative stress
hasbeendemonstratedbyoverexpressionofimmunoreactive
HO-1 protein in neurons and astrocytes of the cerebral
cortex and hippocampus. HO-1 was found to be colocalized
to senile plaques, neuroﬁbrillary tangles, and corpora amy-
lacea [73]. It is widely accepted that a moderate activation
of heme catabolism is neuroprotective and contributes to
degradation of neurotoxic protein aggregates. Regulatory
interactions between HO-1 and COX pathways have also
been reported [74]. However, experimental observations
indicate that the extent of HO-1 induction may be critical
because excessive heme degradation may result in toxic levels
of carbon monoxide, bilirubin and iron. Pharmacological
modulation of HO-1 levels in the brain shows promising
results in models of AD and Parkinson’s disease [75].
Referring to the oxidative stress underlying AD pathol-
ogy, one further aspect of these reactive oxygen species
includes activation of COX-1/2, which are blocked by
NSAIDs. It has been shown that daily doses of NSAIDs6 International Journal of Alzheimer’s Disease
increasecirculating levels of antioxidants [76].Ina ratmodel
ofADitwassuggestedthattreatmentwithaCOX-2inhibitor
reduces oxidative stress and might therefore be beneﬁcial for
the course of AD [77].
As another mechanism it has been suggested that
NSAIDs directly aﬀect amyloid pathology in the brain by
reducing Aβ-42 peptide levels over the gamma-secretase
activity independently of COX activity [78]. Weggen et
al. reported that the NSAIDs ibuprofen, indomethacin,
and sulindac sulphide preferentially decrease the highly
amyloidogenic Aβ-42 peptide produced from a variety of
c u l t u r e dc e l l sb ya sm u c ha s8 0 %[ 79]. However, for some
NSAIDs the lowering eﬀect of Aβ-42 could not be shown;
instead, an increase in Aβ-42 levels was observed [80].
The underlying mechanism of how NSAIDs decrease Aβ-42
was clariﬁed by Lleo et al., who demonstrated that Aβ-42
lowering NSAIDs speciﬁcally aﬀect the proximity between
APP and presenilin 1 and alter a novel allosteric mechanism
of action [81].
8. Anti-InﬂammatoryTreatmentStudies inAD
In recent years it has become widely accepted that inﬂamma-
tory processes are an underlying condition of AD. Therefore
a number of clinical trials investigating diﬀerent anti-
inﬂammatory treatment regimens have been performed. In
the following paragraph, we summarize the most import
ﬁndings in regard to ﬁrst mainly COX-2 dominant and
second COX-1 inhibitors.
A prospective cohort study with 6989 subjects showed
t h a tl o n g - t e r mu s eo fN S A I D sp r o t e c t sa g a i n s tA Db u t
not against vascular dementia [5]. More recently, Szekely
et al. provided very similar ﬁndings: they concluded that
NSAIDs use reduced the risk of preferentially AD versus
vascular dementia but mainly in those individuals having an
apolipoprotein E (APO) epsilon 4 allele. This study was done
with over 3,000 subjects aged 65 years and older [6]. Not
only selective COX-2 inhibitors were shown to be associated
with decreased risk of AD; a reduced occurrence of AD could
also be demonstrated for the use of the COX-1 inhibitor
aspirin [7]. A meta-analysis of 17 epidemiological studies
yielded strong, generally consistent, statistical evidence that
NSAID and steroid use is associated with reduced risk of
AD [82]. Vlad et al. investigated 49,349 patients with AD
and 196,850 controls: long-term (>5 years) nonsteroidal
anti-inﬂammatory drug use was shown to be protective
against Alzheimer disease. These ﬁndings were clearest for
ibuprofen, but did not appear for other NSAIDs [83].
Not all studies showed a positive outcome for COX
inhibitors in AD patients: the failure of selective COX-2
inhibition (rofecoxib) over placebo was stated in a one-
year randomized controlled study. The authors argued that
their results could indicate that the disease process was
too advanced to be modiﬁed, as the goal of the study
was slowing the progression of dementia in patients with
already established AD [8]. For another COX-2 inhibitor,
celecoxib, no beneﬁcial eﬀect on the occurrence of AD
c o u l db ed e m o n s t r a t e di na na g eg r o u po v e r7 0y e a r s[ 84].
Also Wolfson et al. looked retrospectively at a case control
population and found no support for a beneﬁcial eﬀect for
NSAIDs in the AD subjects [85]. However, this negative
result may have been caused by an insuﬃcient period of data
collection before disease onset.
9. Conclusion
It is indisputable that neuroinammation plays a key role
in AD pathology. Mechanisms that parallel those encoun-
tered in localized peripheral inammatory responses are
readily identied, along with detailed pathways for how
the mechanisms interact. On balance, it is likely that AD
neuroinammation exacerbates AD pathogenesis.
A general treatment principle in psychiatry, that an
intervention as early as possible leads to the best outcome,
seems to be especially true for AD. Many lines of evidence
show that Aβ-induced neuroinﬂammation is an early event
in neurodegeneration of AD [86], as increases in microglial
a c t i v a t i o nh a sb e e no b s e r v e di nv e r ye a r l ys t a g e so fA Da n d
disappearedovertime[37].Thefactthatneuroinﬂammation
occursveryearlyinADcouldexplainwhyanti-inﬂammatory
treatment seems to be most eﬃcient as preventive or early
treatment. There are several reasons why an early use of
NSAIDs is superior to a late one: Cox-expression in the
brain decreases over time in AD brains [87]. And the
C S FP GE 2 levels in patients with Alzheimer’s disease were
high when their short-term memory scores were just below
those of controls, but were low in later stages of the
disease. These ﬁndings further support that inﬂammatory
processes predominate early in Alzheimer’s disease [88]a n d
therefore require early intervention with anti-inﬂammatory
treatment.
Thiscouldexplainthefailureofsomeprospectiveclinical
trials of selective COX-2 inhibitors: it may be related to
a delayed onset of treatment, but eventually also to drug
selection (regarding diﬀerent eﬀects of COX-1 and COX-
2) and dose and duration of treatment. Especially the drug
s e l e c t i o ns e e m se s s e n t i a la ss o m eN S A I D sh a v er e c e n t l yb e e n
shown to increase Aβ-42 levels [77]. It also has to be noted
that the protective eﬀects of NSAIDs may be via non-COX-
inhibitory mechanisms, such as lowering of Aβ levels and
activation of the peroxisome proliferator-activated receptor-
[gamma] [89] and these non-COX-dependent mechanisms
might be diﬀerentially distributed among COX-inhibitors.
However, two major aspects should be kept in mind
when considering the signiﬁcance of COX-2 activity in
brain diseases. The ﬁrst thing: COX-2 is expressed under
normal conditions and contributes to fundamental brain
functions such as synaptic activity, memory consolidation,
and functional hyperemia. The second thing: the term
neuroinﬂammation is a much more controlled reaction than
inﬂammation in peripheral tissues. In degenerative diseases,
it mainly occurs in the absence of blood-borne inﬁltrating
cells and is sustained by activated glial cells, particularly
microglia.
In summary, the harmful inﬂammatory processes seem
to dominate AD pathology, butthere are alsosome beneﬁcial
functionsforinﬂammatorysubsets.IfADneuroinammation
is approached with realistic expectations and rational drugInternational Journal of Alzheimer’s Disease 7
design, AD patients could signiﬁcantly beneﬁt from anti-
inammatory treatment, especially with NSAIDs.
A future goal could be to utilize not only the eﬃcient
treatment properties of NSAIDs in early AD, but also makes
use of the neuroprotective aspects of neuroinﬂammation
with a combination therapy that maximizes the potential of
glial activation. This would include treatment with NSAIDs
and drugs that enforce anti-inﬂammatory and antioxidative
properties (e.g. with 3-HAA and HO-1 enhancement).
References
[1] J. G¨ otz and N. N. G¨ otz, “Animal models for Alzheimer’s
disease and frontotemporal dementia: a perspective,” ASN
Neuro, vol. 1, no. 4, article e00019, 2009.
[2] C. E. Teunissen, M. P. J. van Boxtel, H. Bosma, et al., “Serum
markers in relation to cognitive functioning in an aging
population: results of the Maastricht Aging Study (MAAS),”
Tijdschrift voor Gerontologie en Geriatrie, vol. 34, no. 1, pp. 6–
12, 2003.
[3] E. G. McGeer and P. L. McGeer, “Neuroinﬂammation in
Alzheimer’s disease and mild cognitive impairment: a ﬁeld in
its infancy,” Journal of Alzheimer’s Disease,v o l .1 9 ,n o .1 ,p p .
355–361, 2010.
[4] H. Akiyama, S. Barger, S. Barnum, et al., “Inﬂammation and
Alzheimer’s disease,” Neurobiology of Aging,v o l .2 1 ,n o .3 ,p p .
383–421, 2000.
[5] B.A.in’tVeld,A.Ruitenberg,A.Hofman,etal.,“Nonsteroidal
antiinﬂammatory drugs and the risk of Alzheimer’s disease,”
The New England Journal of Medicine, vol. 345, no. 21, pp.
1515–1521, 2001.
[6] C. A. Szekely, J. C. S. Breitner, A. L. Fitzpatrick, et al., “NSAID
useanddementiariskintheCardiovascularHealthStudy:role
of APOE and NSAID type,” Neurology, vol. 70, no. 1, pp. 17–
24, 2008.
[7] J. C. Anthony, J. C. S. Breitner, P. P. Zandi, et al., “Reduced
prevalence of AD in users of NSAIDS and H2 receptor
antagonists: the Cache County study,” Neurology, vol. 54, no.
11, pp. 2066–2071, 2000.
[ 8 ]S .A .R e i n e s ,G .A .B l o c k ,J .C .M o r r i s ,e ta l . ,“ N oe ﬀect
on Alzheimer’s disease in a 1-year, randomized, blinded,
controlled study,” Neurology, vol. 62, no. 1, pp. 66–71, 2004.
[ 9 ]J .K i p n i s ,H .C o h e n ,M .C a r d o n ,Y .ZI V ,a n dM .S c h w a r t z ,
“T cell deﬁciency leads to cognitive dysfunction: implications
for therapeutic vaccination for schizophrenia and other
psychiatric conditions,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 101, no. 21, pp.
8180–8185, 2004.
[10] Y. Ziv, N. Ron, O. Butovsky, et al., “Immune cells contribute to
the maintenance of neurogenesis and spatial learning abilities
in adulthood,” Nature Neuroscience, vol. 9, no. 2, pp. 268–275,
2006.
[11] T. Wyss-Coray, “Inﬂammation in Alzheimer disease: driving
force, bystander or beneﬁcial response?” Nature Medicine, vol.
12, no. 9, pp. 1005–1015, 2006.
[12] P.Edison,H.A.Archer,A.Gerhard,etal.,“Microglia,amyloid,
and cognition in Alzheimer’s disease: an [11C](R)PK11195-
PET and [11C]PIB-PET study,” Neurobiology of Disease, vol.
32, no. 3, pp. 412–419, 2008.
[13] J. Rogers and Y. Shen, “A perspective on inﬂammation in
Alzheimer’s disease,” Annals of the New York Academy of
Sciences, vol. 924, pp. 132–135, 2000.
[14] V. H. Perry, T. A. Newman, and C. Cunningham, “The impact
of systemic infection on the progression of neurodegenerative
disease,” Nature Reviews Neuroscience, vol. 4, no. 2, pp. 103–
112, 2003.
[15] E. Mulugeta, F. Molina-Holgado, M. S. Elliott, et al., “Inﬂam-
matory mediators in the frontal lobe of patients with mixed
and vascular dementia,” Dementia and Geriatric Cognitive
Disorders, vol. 25, no. 3, pp. 278–286, 2008.
[16] S. St¨ ubner, T. Sch¨ on, F. Padberg, et al., “Interleukin-6 and
the soluble IL-6 receptor are decreased in cerebrospinal ﬂuid
of geriatric patients with major depression: no alteration of
soluble gp130,” Neuroscience Letters, vol. 259, no. 3, pp. 145–
148, 1999.
[17] X.-Q. Wang, Y.-P. Peng, J.-H. Lu, B.-B. Cao, and Y.-H. Qiu,
“Neuroprotection of interleukin-6 against NMDA attack and
its signal transduction by JAK and MAPK,” Neuroscience
Letters, vol. 450, no. 2, pp. 122–126, 2009.
[18] L.-F. Lue, L. Brachova, W. H. Civin, and J. Rogers, “Inﬂamma-
tion, Aβ deposition, and neuroﬁbrillary tangle formation as
correlates of Alzheimer’s disease neurodegeneration,” Journal
of Neuropathology and Experimental Neurology, vol. 55, no. 10,
pp. 1083–1088, 1996.
[19] S. Webster, L.-F. Lue, L. Brachova, et al., “Molecular and
cellular characterization of the membrane attack complex,
C5b-9, in Alzheimer’s disease,” Neurobiology of Aging, vol. 18,
no. 4, pp. 415–421, 1997.
[20] P. del Rio-Hortega, “Art and artiﬁce in the science of
histology,” Histopathology, vol. 22, no. 6, pp. 515–525, 1993.
[21] M. L. Block, L. Zecca, and J.-S. Hong, “Microglia-mediated
neurotoxicity:uncoveringthemolecularmechanisms,”Nature
Reviews Neuroscience, vol. 8, no. 1, pp. 57–69, 2007.
[22] P. Cras, M. Kawai, S. Siedlak, et al., “Neuronal and microglial
involvement in β-amyloid protein deposition in Alzheimer’s
disease,” American Journal of Pathology, vol. 137, no. 2, pp.
241–246, 1990.
[23] S. D. Styren, W. H. Civin, and J. Rogers, “Molecular, cellular,
and pathologic characterization of HLA-DR immunoreac-
tivity in normal elderly and Alzheimer’s disease brain,”
Experimental Neurology, vol. 110, no. 1, pp. 93–104, 1990.
[24] L. S. Perlmutter, E. Barron, and H. C. Chui, “Morphologic
association between microglia and senile plaque amyloid in
Alzheimer’s disease,” Neuroscience Letters, vol. 119, no. 1, pp.
32–36, 1990.
[25] L.-F. Lue, R. Rydel, E. F. Brigham, et al., “Inﬂammatory
repertoire of Alzheimer’s disease and nondemented elderly
microglia in vitro,” GLIA, vol. 35, no. 1, pp. 72–79, 2001.
[26] A. R. Simard and S. Rivest, “Bone marrow stem cells have the
ability to populate the entire central nervous system into fully
diﬀerentiated parenchymal microglia,” FASEB Journal, vol. 18,
no. 9, pp. 998–1000, 2004.
[27] A. Majumdar, D. Cruz, N. Asamoah, et al., “Activation of
microglia acidiﬁes lysosomes and leads to degradation of
Alzheimer amyloid ﬁbrils,” Molecular Biology of the Cell, vol.
18, no. 4, pp. 1490–1496, 2007.
[28] J. Koenigsknecht-Talboo and G. E. Landreth, “Microglial
phagocytosis induced by ﬁbrillar β-amyloid and IgGs are dif-
ferentiallyregulatedbyproinﬂammatorycytokines,”Journalof
Neuroscience, vol. 25, no. 36, pp. 8240–8249, 2005.
[29] R. Fan, F. Xu, M. L. Previti, et al., “Minocycline reduces
microglial activation and improves behavioral deﬁcits in a
transgenic model of cerebral microvascular amyloid,” Journal
of Neuroscience, vol. 27, no. 12, pp. 3057–3063, 2007.8 International Journal of Alzheimer’s Disease
[ 3 0 ]T .J .S e a b r o o k ,L .J i a n g ,M .M a i e r ,a n dC .A .L e m e r e ,
“Minocycline aﬀects microglia activation, Aβ deposition, and
behavior in APP-tg mice,” GLIA, vol. 53, no. 7, pp. 776–782,
2006.
[31] C. Chaves, C. R. Marque, C. Trzesniak, et al., “Glutamate-
N-methyl-D-aspartate receptor modulation and minocycline
for the treatment of patients with schizophrenia: an update,”
Brazilian Journal of Medical and Biological Research, vol. 42,
no. 11, pp. 1002–1014, 2009.
[32] T. Wyss-Coray, C. Lin, F. Yan, et al., “TGF-β1p r o m o t e s
microglial amyloid-β clearance and reduces plaque burden in
transgenic mice,” Nature Medicine, vol. 7, no. 5, pp. 612–618,
2001.
[33] M. Persson, M. Brantefjord, E. Hansson, and L. R¨ onnb¨ ack,
“Lipopolysaccharide increases microglial GLT-1 expression
and glutamate uptake capacity in vitro by a mechanism
dependentonTNF-α,” GLIA,vol.51,no.2,pp.111–120,2005.
[34] P. T. Francis, “Altered glutamate neurotransmission and
behaviour in dementia: evidence from studies of memantine,”
CurrentMolecularPharmacology,vol.2,no.1,pp.77–82,2009.
[35] S. U. Kim and J. de Vellis, “Microglia in health and disease,”
Journal of Neuroscience Research, vol. 81, no. 3, pp. 302–313,
2005.
[36] U.-K. Hanisch and H. Kettenmann, “Microglia: active sensor
andversatileeﬀectorcellsinthenormalandpathologicbrain,”
Nature Neuroscience, vol. 10, no. 11, pp. 1387–1394, 2007.
[ 3 7 ]A .K .V e h m a s ,C .H .K a w a s ,W .F .S t e w a r t ,a n dJ .C .T r o n c o s o ,
“Immune reactive cells in senile plaques and cognitive decline
in Alzheimer’s disease,” Neurobiology of Aging, vol. 24, no. 2,
pp. 321–331, 2003.
[ 3 8 ]E .J .R e m a r q u e ,E .L .E .M .B o l l e n ,A .W .E .W e v e r l i n g -
Rijnsburger, J. C. Laterveer, G. J. Blauw, and R. G. J.
Westendorp, “Patients with Alzheimer’s disease display a pro-
inﬂammatory phenotype,” Experimental Gerontology, vol. 36,
no. 1, pp. 171–176, 2001.
[39] N. G. Innamorato, I. Lastres-Becker, and A. Cuadrado, “Role
of microglial redox balance in modulation of neuroinﬂamma-
tion,” Current Opinion in Neurology, vol. 22, no. 3, pp. 308–
314, 2009.
[40] M. G. Espey, O. N. Chernyshev, J. F. Reinhard Jr., M. A. A.
Namboodiri, and C. A. Colton, “Activated human microglia
produce the excitotoxin quinolinic acid,” NeuroReport, vol. 8,
no. 2, pp. 431–434, 1997.
[41] D. Giulian, “Senile plaques stimulate microglia to release
a neurotoxin found in Alzheimer brain,” Neurochemistry
International, vol. 27, no. 1, pp. 119–137, 1995.
[42] G. Leipnitz, C. Schumacher, K. B. Dalcin, et al., “In vitro
evidence for an antioxidant role of 3-hydroxykynurenine
and 3-hydroxyanthranilic acid in the brain,” Neurochemistry
International, vol. 50, no. 1, pp. 83–94, 2007.
[43] S. R. Thomas, P. K. Witting, and R. Stocker, “3-
hydroxyanthranilic acid is an eﬃcient, cell-derived co-
antioxidant for α-tocopherol, inhibiting human low density
lipoprotein and plasma lipid peroxidation,” Journal of
Biological Chemistry, vol. 271, no. 51, pp. 32714–32721, 1996.
[44] W. L. Smith, R. Michael Garavito, and D. L. DeWitt,
“Prostaglandin endoperoxide H syntheses (cyclooxygenases)-
1a n d- 2 , ”Journal of Biological Chemistry, vol. 271, no. 52, pp.
33157–33160, 1996.
[45] P. S. Aisen and K. L. Davis, “The search for disease-modifying
treatment for Alzheimer’s disease,” Neurology, vol. 48, no. 5,
pp. S35–S41, 1997.
[46] W. D. Hirst, K. A. Young, R. Newton, V. C. Allport, D. R.
Marriott, and G. P. Wilkin, “Expression of COX-2 by normal
andreactiveastrocytesintheadultratcentralnervoussystem,”
Molecular and Cellular Neurosciences, vol. 13, no. 1, pp. 57–68,
1999.
[47] B.Hauss-Wegrzyniak,P.Vraniak,andG.L.Wenk,“Theeﬀects
of a novel NSAID on chronic neuroinﬂammation are age
dependent,” Neurobiology of Aging, vol. 20, no. 3, pp. 305–313,
1999.
[ 4 8 ] A .M .P l a n a s ,M .A .S o ri a n o ,E .R o d r ´ ıquez-Farr´ e, and I. Ferrer,
“Induction of cyclooxygenase-2 mRNA and protein following
transient focal ischemia in the rat brain,” Neuroscience Letters,
vol. 200, no. 3, pp. 187–190, 1995.
[49] G.Tocco,J.Freire-Moar,S.S.Schreiber,S.H.Sakhi,P.S.Aisen,
and G. M. Pasinetti, “Maturational regulation and regional
induction of cyclooxygenase-2 in rat brain: implications for
Alzheimer’s disease,” Experimental Neurology, vol. 144, no. 2,
pp. 339–349, 1997.
[50] G. M. Pasinetti and P. S. Aisen, “Cyclooxygenase-2 expression
is increased in frontal cortex of Alzheimer’s disease brain,”
Neuroscience, vol. 87, no. 2, pp. 319–324, 1998.
[51] Y. Matsuoka, M. Picciano, B. Maleste, et al., “Inﬂammatory
responses to amyloidosis in a transgenic mouse model of
Alzheimer’s disease,” American Journal of Pathology, vol. 158,
no. 4, pp. 1345–1354, 2001.
[52] S. J. Hewett, T. F. Uliasz, A. S. Vidwans, and J. A. Hewett,
“Cyclooxygenase-2 contributes to N-methyl-D-aspartate-
mediated neuronal cell death in primary cortical cell culture,”
Journal of Pharmacology and Experimental Therapeutics, vol.
293, no. 2, pp. 417–425, 2000.
[53] L. B. Willard, B. Hauss-Wegrzyniak, W. Danysz, and G. L.
Wenk, “The cytotoxicity of chronic neuroinﬂammation upon
basal forebrain cholinergic neurons of rats can be attenuated
by glutamatergic antagonism or cyclooxygenase-2 inhibition,”
Experimental Brain Research, vol. 134, no. 1, pp. 58–65, 2000.
[54] T. Kunz and E. H. Oliw, “The selective cyclooxygenase-2
inhibitor rofecoxib reduces kainate-induced cell death in the
rat hippocampus,” European Journal of Neuroscience, vol. 13,
no. 3, pp. 569–575, 2001.
[55] E. Araki, C. Forster, J. M. Dubinsky, M. E. Ross, and
C. Iadecola, “Cyclooxygenase-2 inhibitor NS-398 protects
neuronal cultures from lipopolysaccharide-induced neurotox-
icity,” Stroke, vol. 32, no. 10, pp. 2370–2375, 2001.
[56] K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Dis-
tribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs
and proteins in human brain and peripheral organs,” Brain
Research, vol. 830, no. 2, pp. 226–236, 1999.
[57] L. Ho, D. Purohit, V. Haroutunian, et al., “Neuronal cyclooxy-
genase 2 expression in the hippocampal formation as a
function of the clinical progression of Alzheimer disease,”
Archives of Neurology, vol. 58, no. 3, pp. 487–492, 2001.
[58] W. J. Lukiw and N. G. Bazan, “Cyclooxygenase 2 RNA
message abundance, stability, and hypervariability in sporadic
Alzheimer neocortex,” Journal of Neuroscience Research, vol.
50, no. 6, pp. 937–945, 1997.
[59] J. W. Chang, P. D. Coleman, and M. K. O’Banion,
“Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA
expression is decreased in Alzheimer’s disease,” Neurobiology
of Aging, vol. 17, no. 5, pp. 801–808, 1996.
[60] T. J. Montine, K. R. Sidell, B. C. Crews, et al., “Elevated
CSF prostaglandin E2 levels in patients with probable AD,”
Neurology, vol. 53, no. 7, pp. 1495–1498, 1999.International Journal of Alzheimer’s Disease 9
[61] R. K. K. Lee, S. Knapp, and R. J. Wurtman, “Prostaglandin
E2 stimulates amyloid precursor protein gene expression:
inhibition by immunosuppressants,” Journal of Neuroscience,
vol. 19, no. 3, pp. 940–947, 1999.
[ 6 2 ]M .A .A .B l o m ,M .G .H .V a nT w i l l e r t ,S .C .d eV r i e s ,e ta l . ,
“NSAIDS inhibit the IL-1 β-induced IL-6 release from human
post-mortem astrocytes: the involvement of prostaglandin
E2,” Brain Research, vol. 777, no. 1-2, pp. 210–218, 1997.
[63] B. L. Fiebich, M. H¨ ull, K. Lieb, K. Gyufko, M. Berger, and J.
Bauer, “Prostaglandin E2 induces interleukin-6 synthesis in
human astrocytoma cells,” Journal of Neurochemistry, vol. 68,
no. 2, pp. 704–709, 1997.
[64] K. A. Kelley, L. Ho, D. Winger, et al., “Potentiation of
excitotoxicity in transgenic mice overexpressing neuronal
cyclooxygenase-2,”AmericanJournalofPathology,vol.155,no.
3, pp. 995–1004, 1999.
[65] G. M. Pasinetti, “Cyclooxygenase and inﬂammation in
Alzheimer’s disease: experimental approaches and clinical
interventions,” Journal of Neuroscience Research, vol. 54, no. 1,
pp. 1–6, 1998.
[66] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit
production of monocyte inﬂammatory cytokines,” Nature,
vol. 391, no. 6662, pp. 82–86, 1998.
[67] J.M.Lehmann,J.M.Lenhard,B.B.Oliver,G.M.Ringold,and
S. A. Kliewer, “Peroxisome proliferator-activated receptors α
and γ are activated by indomethacin and other non-steroidal
anti-inﬂammatory drugs,” Journal of Biological Chemistry, vol.
272, no. 6, pp. 3406–3410, 1997.
[68] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K.
Glass, “The peroxisome proliferator-activated receptor-γ is a
negativeregulatorofmacrophageactivation,”Nature,vol.391,
no. 6662, pp. 79–82, 1998.
[69] C. K. Combs, D. E. Johnson, S. B. Cannady, T. M. Lehman,
and G. E. Landreth, “Identiﬁcation of microglial signal
transduction pathways mediating a neurotoxic response to
amyloidogenic fragments of β-amyloid and prion proteins,”
Journal of Neuroscience, vol. 19, no. 3, pp. 928–939, 1999.
[ 7 0 ]C .K .C o m b s ,D .E .J o h n s o n ,J .C .K a r l o ,S .B .C a n n a d y ,a n d
G. E. Landreth, “Inﬂammatory mechanisms in Alzheimer’s
disease: inhibition of β-amyloid-stimulated proinﬂammatory
responses and neurotoxicity by PPARγ agonists,” Journal of
Neuroscience, vol. 20, no. 2, pp. 558–567, 2000.
[71] M. A. Ansari and S. W. Scheﬀ, “Oxidative stress in the
progression of alzheimer disease in the frontal cortex,” Journal
of Neuropathology and Experimental Neurology, vol. 69, no. 2,
pp. 155–167, 2010.
[72] M. A. Smith, X. Zhu, M. Tabaton, et al., “Increased iron and
free radical generation in preclinical Alzheimer disease and
mild cognitive impairment,” Journal of Alzheimer’s Disease,
vol. 19, no. 1, pp. 353–372, 2010.
[73] H. M. Schipper, W. Song, H. Zukor, J. R. Hascalovici, and
D. Zeligman, “Heme oxygenase-1 and neurodegeneration:
expanding frontiers of engagement,” Journal of Neurochem-
istry, vol. 110, no. 2, pp. 469–485, 2009.
[74] M. J. Alcaraz, P. Fernandez, and M. I. Guill´ en, “Anti-
inﬂammatory actions of the heme oxygenase-1 pathway,”
Current Pharmaceutical Design, vol. 9, no. 30, pp. 2541–2551,
2003.
[ 7 5 ]A .C u a d r a d oa n dA .I .R o j o ,“ H e m eo x y g e n a s e - 1a sa
therapeutic target in neurodegenerative diseases and brain
infections,” Current Pharmaceutical Design,v o l .1 4 ,n o .5 ,p p .
429–442, 2008.
[76] K.Kimura,“Mechanismsofactiveoxygenspeciesreductionby
non-steroidal anti-inﬂammatory drugs,” International Journal
of Biochemistry and Cell Biology, vol. 29, no. 3, pp. 437–446,
1997.
[77] M. Nivsarkar, A. Banerjee, and H. Padh, “Cyclooxygenase
inhibitors: a novel direction for Alzheimer’s management,”
Pharmacological Reports, vol. 60, no. 5, pp. 692–698, 2008.
[78] C. Guardia-Laguarta, M. Pera, and Lle´ oA ,“ γ-secretase as
a therapeutic target in Alzheimer’s disease,” Current Drug
Targets, vol. 11, no. 4, pp. 506–517, 2010.
[79] S. Weggen, J. L. Eriksen, P. Das, et al., “A subset of NSAIDs
lower amyloidogenic Aβ42 independently of cyclooxygenase
activity,” Nature, vol. 414, no. 6860, pp. 212–216, 2001.
[80] T. Kukar, M. P. Murphy, J. L. Eriksen, et al., “Diverse
compounds mimic Alzheimer disease-causing mutations by
augmenting Aβ42 production,” Nature Medicine, vol. 11, no.
5, pp. 545–550, 2005.
[81] A. Lle´ o, O. Berezovska, L. Herl, et al., “Nonsteroidal anti-
inﬂammatory drugs lower Aβ42 and change presenilin 1
conformation,” Nature Medicine, vol. 10, no. 10, pp. 1065–
1066, 2004.
[82] P. L. McGeer, M. Schulzer, and E. G. McGeer, “Arthritis and
anti-inﬂammatory agents as possible protective factors for
Alzheimer’s disease: a review of 17 epidemiologic studies,”
Neurology, vol. 47, no. 2, pp. 425–432, 1996.
[83] S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson, “Pro-
tective eﬀects of NSAIDs on the development of Alzheimer
disease,” Neurology, vol. 70, no. 19, pp. 1672–1677, 2008.
[84] B. K. Martin, C. Szekely, J. Brandt, et al., “Cognitive func-
tion over time in the Alzheimer’s disease anti-inﬂammatory
prevention trial (ADAPT): results of a randomized, controlled
trial of naproxen and celecoxib,” Archives of Neurology, vol. 65,
no. 7, pp. 896–905, 2008.
[85] C.Wolfson,A.Perrault,Y.Moride,J.M.Esdaile,L.Abenhaim,
and F. Momoli, “A case-control analysis of nonsteroidal
anti-inﬂammatory drugs and Alzheimer’s disease: are they
protective?”Neuroepidemiology,vol.21,no.2,pp.81–86,2002.
[86] J. M. Craft, D. M. Watterson, and L. J. Van Eldik, “Human
amyloid β-induced neuroinﬂammation is an early event in
neurodegeneration,” GLIA, vol. 53, no. 5, pp. 484–490, 2006.
[87] A. V. Yermakova and M. Kerry O’Banion, “Downregula-
tion of neuronal cyclooxygenase-2 expression in end stage
Alzheimer’s disease,” Neurobiology of Aging,v o l .2 2 ,n o .6 ,p p .
823–836, 2001.
[88] M. Combrinck, J. Williams, M. A. De Berardinis, et al., “Levels
of CSF prostaglandin E2, cognitive decline, and survival in
Alzheimer’s disease,” Journal of Neurology, Neurosurgery and
Psychiatry, vol. 77, no. 1, pp. 85–88, 2006.
[89] P. S. Aisen, “The potential of anti-inﬂammatory drugs for the
treatment of Alzheimer’s disease,” Lancet Neurology, vol. 1, no.
5, pp. 279–284, 2002.